A Phase 3 interventional study of Empagliflozin 10 MG and Placebo in Acute Heart Failure, sponsored by Juntendo University. Recruiting at 69 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Juntendo University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.
Among the 51 studies testing empagliflozin in Heart Failure, this one is the 8th largest by planned enrollment, is one of 10 that started in 2022, is one of 14 in phase 3, reaches primary completion later than 12 of the 21 other live ones, and was the 23rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Christian Schulze · Sites in Germany
Ages 18+
Ain Shams University · Sites in Egypt
Ages 1 mo–18 yrs
University of Alberta · Sites in Canada
Ages 18+
Fazaia Ruth Pfau Medical College · Sites in Pakistan
Ages 40–70
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 15 · Phase 4 16
First in 2017; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 444 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 90 across the 51 interventional studies. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 51 have an industry lead sponsor. The 10 most frequent:
Juntendo University is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Juntendo University has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
8 of the studies testing empagliflozin in Heart Failure that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05392764Phase 3Juntendo UniversityEarly Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure | 2026-12-31 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT07038356Phase 3Christian SchulzeEffects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure | 2027-04-30 |
| NCT07692256Ain Shams Universitythe Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients | 2026-12-01 |
| NCT06260059Anita SarafEfficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 51 studies testing empagliflozin in Heart Failure, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet the below inclusion criteria will be randomized within 12 h after presentation to the hospital
Hospitalized with a diagnosis of acute heart failure, requiring intravenous loop diuretic therapy, and with all of the following characteristics:
i. Dyspnoea at rest or induced by slight exertion ii. At least two of the following findings: jugular venous distention, pulmonary rales, lower leg edema, and pulmonary congestion on chest X-ray iii. If the patient has a sinus rhythm at the time of admission, BNP ≥350 pg/mL or NT-proBNP ≥1400 pg/mL; if the patient has atrial fibrillation at the time of admission, BNP ≥500 pg/mL or NT-proBNP ≥2000 pg/mL. For patients taking an angiotensin receptor neprilysin inhibitor, only the reference value for NT-proBNP will be applicable.
At least one of the following characteristics:
i. \<60 mL/min/1.73m2, as calculated using the CKD Epidemiology Collaboration for JapaneseModification of Diet in Renal Disease formula ii. Already taking ≥40 mg of oral furosemide during the period before hospitalization. For patients on loop diuretics other than furosemide, the following conversion should be used: oral furosemide 20 mg = oral azosemide 30 mg = oral torasemide 5 mg.
iii. Urine output of \<300 mL during the 2 h following an appropriate dose of intravenous furosemide administered after hospitalization. An appropriate dose of intravenous furosemide is 20 mg for patients who have not been taking furosemide regularly before hospitalization and is the same as, or greater than, the daily oral dose for patients who have been taking furosemide regularly before hospitalization.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be randomized 1:1 to either empagliflozin or placebo.
Drug: Empagliflozin 10 MG
Placebo matching empagliflozin
Drug: Placebo
once-daily oral empagliflozin 10 mg
Placebo matching empagliflozin 10 mg
A hierarchical composite endpoint consisting of death within 90 days, heart failure rehospitalization within 90 days, WHF during hospitalization, and urine output up to 48 hours after treatment initiation, assessed by the win ratio
WHF, worsening heart failure
Time frame: Up to 90 days
A hierarchical composite endpoint consisting of death within 90 days, heart failure readmission within 90 days, and WHF during hospitalization
WHF, worsening heart failure
Time frame: Up to 90 days
A composite endpoint consisting of WHF during hospitalization, death, heart failure rehospitalization, urgent visit for WHF, intensification of diuretic therapy, and worsening NYHA class within 90 days
WHF, worsening heart failure
Time frame: Up to 90 days
Change in NT-proBNP from randomization to 48 hours
Time frame: Evaluated at 48 hours after randomization
Diuretic response, calculated as urine output achieved by loop diuretics (40 mg intravenous furosemide-equivalent dose) at 48 h after treatment initiation
Time frame: Evaluated at 48 hours after randomization
Improvement in KCCQ-TSS of ≥5 points from randomization to 30 and 90 days after treatment initiation
KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire - Total Symptom Score. The scores range from 0 to 100, with 100 being the best possible score.
Time frame: Up to 90 days
Time to hemodynamic stabilization during index hospitalization
Time frame: During index hospitalization
Re-worsening of heart failure during index hospitalization
Time frame: During index hospitalization
Heart failure rehospitalization
Time frame: Up to 90 days
Death
Time frame: Up to 90 days
Urine output during the 48 h after randomization
Time frame: Evaluated at 48 hours after randomization
Cardiovascular death
Time frame: Up to 90 days
Change in the visual analog scale score for dyspnea from after randomization to 24 and 48 h
The scores range from 0 to 100, with 100 being the best possible score.
Time frame: Evaluated at 24 and 48 hours after randomization
Change in high sensitivity cardiac troponin T
Time frame: Evaluated at 48 hours after randomization
Change in the KCCQ-TSS after randomization to 30 and 90 days
KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire - Total Symptom Score. The scores range from 0 to 100, with 100 being the best possible score.
Time frame: Up to 90 days
Composite of renal replacement therapy, renal transplantation, eGFR <15 mL/min/1.73m2, ≥50% decrease in eGFR compared to the first sample or a ≥2-fold increase in creatinine level compared to the first sample within 90 days of randomization
Time frame: Up to 90 days
Trend in eGFR after randomization to 24 h, 48 h, 30 days, and 90 days
Time frame: Up to 90 days
Days alive and out of hospital (including those for reasons other than heart failure)
Time frame: Up to 90 days
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.
Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 51 months is close to that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin
Juntendo University